Merck & Co., Inc. (NYSE:MRK) Sets New 1-Year High - What's Next?

Key Points

• Merck shares reached a new 52-week high of $132.12, closing around $131.81 and trading above both the 50-day and 200-day moving averages.
• Analysts maintain a broadly positive outlook, with a “Moderate Buy” consensus and an average price target of $133.94; recent targets range from $140 to $145 among several bullish firms.
• Merck’s latest quarterly results beat expectations on both earnings and revenue, while the company continues to pay a quarterly dividend of $0.85 per share, representing a 2.6% yield.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) shares hit a new 52-week high during trading on Monday . The company traded as high as $132.12 and last traded at $131.81, with a volume of 455652 shares changing hands. The stock had previously closed at $131.07.

Analyst Ratings Changes

A number of brokerages recently commented on MRK. Bank of America upped their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a "buy" rating in a research note on Tuesday, June 30th. Royal Bank Of Canada restated an "outperform" rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a report on Wednesday, July 8th. Cantor Fitzgerald reissued a "neutral" rating and set a $120.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Guggenheim lifted their price target on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the company a "buy" rating in a report on Monday, July 13th. Finally, JPMorgan Chase & Co. upped their target price on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an "overweight" rating in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $133.94.

Merck & Co., Inc. Stock Up 0.9%

The company's fifty day moving average is $121.67 and its 200-day moving average is $117.78. The company has a market cap of $326.50 billion, a PE ratio of 37.24, a PEG ratio of 5.20 and a beta of 0.19. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. The firm had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business's revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, analysts predict that Merck & Co., Inc. will post 2.74 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th were given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.6%. The ex-dividend date was Monday, June 15th. Merck & Co., Inc.'s dividend payout ratio is currently 95.77%.

Institutional Trading of Merck & Co., Inc.

Several institutional investors and hedge funds have recently made changes to their positions in MRK. Somerset Trust Co raised its holdings in shares of Merck & Co., Inc. by 0.9% in the second quarter. Somerset Trust Co now owns 8,701 shares of the company's stock valued at $1,118,000 after acquiring an additional 81 shares in the last quarter. Stonebridge Financial Group LLC lifted its holdings in shares of Merck & Co., Inc. by 0.9% in the 2nd quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company's stock valued at $1,124,000 after buying an additional 81 shares during the period. Stronghold Wealth Management L.L.C. boosted its holdings in Merck & Co., Inc. by 2.6% during the second quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company's stock worth $416,000 after buying an additional 82 shares in the last quarter. Lederer & Associates Investment Counsel CA boosted its position in Merck & Co., Inc. by 0.9% during the second quarter. Lederer & Associates Investment Counsel CA now owns 9,603 shares of the company's stock worth $1,234,000 after purchasing an additional 84 shares in the last quarter. Finally, Pine Haven Investment Counsel Inc grew its stake in Merck & Co., Inc. by 0.6% in the 2nd quarter. Pine Haven Investment Counsel Inc now owns 14,273 shares of the company's stock valued at $1,834,000 after acquiring an additional 86 shares during the period. 76.07% of the stock is currently owned by institutional investors.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.